Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
interesting press release on web site, hiring top notch marketing company
NO DEVELOPMENT COMPANY BRISTOL-MAYERS SQUIBB.PITY.
If it involves
Amaran Biotechnology
Neovacs
Araclon Biotech SL
Bayer Innovation GMBH
then they are.
NEWS COMING OUT OF UK CONCERNING IMMUNOTHERAPIES TREATMENT FOR MELANOMA CANCER WITH 60% SUCCESS RATE IS GOOD NEWS. ARE SBOTF PARTNERED WITH THE DRUG COMPANIES INVOLVED WITH KLM AS DELIVERY MECHANISM?
CANT REALLY DECIDE WHETHER SBOTF has not got time to support investors or its a lack of interest in pps but a PR of what is happening would be nice every now and then
PORT HUENEME, CA -- (Marketwired) -- 05/14/15 -- Stellar Biotechnologies, Inc. ("Stellar" or the "Company") (OTCQB: SBOTF) (TSX VENTURE: KLH), the leader in sustainable manufacture of Keyhole Limpet Hemocyanin (KLH), today announced that the Company is expanding its online corporate communications channels to include Twitter, Facebook, and Google+/YouTube.
Stellar's corporate website www.stellarbiotech.com will remain its primary channel of communication to shareholders. The Company's announcements will be posted to Twitter and Facebook after they are first posted on the website. Stellar plans to use the additional online channels to communicate educational content and general information about the Company's technology, industry and activities.
Links to all of Stellar's communications tools are listed here:
Stellar Biotechnologies corporate website: www.stellarbiotech.com
Facebook: https://www.facebook.com/StellarBiotech
Twitter: https://twitter.com/StellarBiotech
Google+: https://plus.google.com/+StellarBiotech/about
KLH Knowledge Base: http://www.klhsite.org/
from your lips...! even a little movement in that direction would be a great confidence booster....
sbotf has a lot of clients waiting for new drug approval perhaps there is movement on some of these
sorta feels like something else might be going on....not sure what, but imho this spike is more than a delayed reaction to financials that weren't THAT great.....fwiw
moving back to their core business was the right move, R/D cost are prohibitive for a small company to bring products to fruition
Looks like they just might be turning the corner.
PORT HUENEME, CA -- (Marketwired) -- 05/11/15 -- Stellar Biotechnologies, Inc. ("Stellar" or "the Company") (OTCQB: SBOTF) (TSX VENTURE: KLH), the leader in sustainable manufacture of Keyhole Limpet Hemocyanin ("KLH"), an important immune-stimulating protein used in wide-ranging immunotherapeutic markets, today announced its financial results for the second fiscal quarter and six months ended March 31, 2015.
"Stellar is pleased to issue this mid-year report which shows increased demand for our products, continued financial prudence, and the positive effect of continued focus on our core KLH business," said Frank Oakes, President and Chief Executive Officer of Stellar Biotechnologies, Inc. "As KLH-based technologies advance through clinical development, we are excited to be in this strong position as the opportunities in the KLH market continue to grow."
is there any body out there?or is it just computers working this stocks price movement?
This is becoming interesting at these prices. Should have another investment firm touting how great this is soon.
read Seeking Alpha 09/23/2014 SBOTF "weve seen the pump... draw your own conclusions
Google Keyhole Limpet hemocyanin and you'll see a link to Alibaba with suppliers ready to ship. I find it strange and wonder where they get their KLH from. Stellar uses the Giant Keyhole Limpet only but I wonder if the other limpet species have the same genetic make up in relation to producing KLH.
Hi cant remember which article it was I read containing this info have a feeling it was a Motley Fool item.Which on reflection was probably a load of BS like most off the articles they produce
That's strange Coddy,India and Isreal?
Also as I recall Stellar is the only one that is capable of extracting without killing the host and also holds proprietary protection for the procedure. I was under the impression that the Keyhole Limpet only inhabited the waters off the southern California coastline.
There is a source in India but they do not extract the KLH and return the limpet to continue growing they extract and discard. so limited stock.In Israel they produce a synthetic version but expensive.What is needed is for the new drugs using KLH under trial get FDA approval
FDA acknowledges the value of KLH yesturday. One question. With various pharmaceutical companies using KLH in labs,Is there another supplier with a traceable and sustainable supply of KLH?
Seems to me that if not, the supply of wild limpet s will not be able keep up with the demand and eventually be granted a threatened classification by the government. When that happens Stellar just might be the only source.
definitely under one buck....any news about the nasdaq uplisting ?
Does the list of the daily sell orders also include short sale orders? I've been seeing sell orders all week but can't imagine who would be selling now.
Definitely interesting..
http://www.csmonitor.com/Science/2015/0221/Snail-teeth-may-be-secret-to-faster-cars.-Really.-video
http://www.cbc.ca/news/technology/limpet-teeth-are-strongest-natural-material-known-1.2965059
http://www.compositesworld.com/news/research-shows-composite-limpet-teeth-among-strongest-material-in-nature
limpet teeth are one of the hardest substances of earth according to new data. perhaps a new source of revenue for Stellar.
Seems that way but managed properly,one by one drugs utilizing KLH will come to fruition.
This is a unique property with limited production that keeps me interested.
Properly Managed.
it would appear they have started to focus on supply (income)and scaled back research.
Coddy....Did you notice the quarterly released today?
More of the same.
1.2 million loss.
Low six figure gain.
But there is a restructuring of reporting time frames which they probably feel will be friendly for the company. Still don't get that one.
Good supply company managed by aquaculture specialist.
Until that changes we can expect more of the same for eternity.
been here forever why? this company has an exclusive product with many companies going through FDA approval that require klm to succeed. just wish good news was more frequent
Any idea why the sudden pop in price?
People haven't realized how big a deal this was...now the word is getting around. It's a small stock & not widely followed:
http://finance.yahoo.com/news/stellar-biotechnologies-araclon-biotech-sign-174343696.html
I wish I picked up at .80
Now it's climbing.
Now under the dollar mark...
That's a good one.
Nice Don Knotts reference.
Codfather,this is a thinly traded stock that has potential but obviously isn't managed to match the potential. I've been in and out of Stellar with success but the first time took over a year before gains were realized. I killed the S&P returns that year.
Yeah, the board is dead and it seems that the only time this rises is with an investment firm touting it. Those days will come to an end and I'll be back in.
anyone out there? the silence is deafening? price is "Limpiting" along
think u could get nick to do another pump so i can get out of this turky
You'd think that the sales would be on the increase two fold YOY.
At least the diffinative agreement silence announced a couple of quarters has been broken.
Stellar is running on 3 cylinders.
SBOTF still a very small company
" Revenues were $372,132 for the fiscal year ended August 31, 2014 compared to $545,469 for the fiscal year ended August 31, 2013.
Revenues included product sales of $143,553 compared to $76,055 for the prior year"
for fiscal year ended august 31
http://www.stellarbiotechnologies.com/media/press-releases/detail/274/stellar-biotechnologies-reports-year-end-2014-financial
Dr.Chow left for personal reasons.
That will be a question next cc
FINALLY HARD FACT GOOD NEWS!
Stellar Biotech to provide KLH for BiovaxID treatment
Ticker Symbol: C:KLH
Stellar Biotech to provide KLH for BiovaxID treatment
Stellar Biotechnologies Inc (C:KLH)
Shares Issued 79,421,650
Last Close 10/22/2014 $1.39
Thursday October 23 2014 - News Release
Mr. Mark McPartland reports
STELLAR BIOTECHNOLOGIES AND BIOVEST INTERNATIONAL SIGN KLH SUPPLY AGREEMENT FOR BIOVAXID IMMUNOTHERAPY FOR FOLLICULAR NON-HODGKIN'S LYMPHOMA
Stellar Biotechnologies Inc. and Biovest International Inc. have executed a definitive supply agreement to meet Biovest's requirements for keyhole limpet hemocyanin (KLH) for use in Biovest's BiovaxID active immunotherapy to treat follicular non-Hodgkin's lymphoma.
Stellar is a leader in sustainable manufacture of KLH, an immune-stimulating protein widely used as a carrier molecule in active immunotherapy drugs in development for certain cancers and other diseases. Stellar manufactures its KLH products under the brand Stellar KLH.
Biovest is a biotechnology company developing and commercializing BiovaxIDtrademark (dasiprotimut-T), an active immunotherapy to treat follicular non-Hodgkin's lymphoma. BiovaxIDtrademark combines autologous heterohybridoma-derived tumor idiotype protein coupled to KLH as the carrier molecule. BiovaxIDtrademark has successfully completed Phase 2 and Phase 3 clinical trial development and is currently the subject of a Marketing Authorization Application (MAA) under review by the European Medicines Agency (EMA).
The purpose of the supply agreement is to establish the terms for the production and supply of Stellar KLH? to Biovest, for use as an active component in BiovaxIDtrademark immunotherapy vaccine in both commercial distribution as well as for future clinical trials.
The supply agreement requires Stellar to deliver Stellar KLH? to Biovest compliant with cGMP standards required for Biovest's ongoing development and as an anticipated commercial supply. Biovest is obligated to purchase Stellar KLH? at agreed forecasted quantities and prices. The supply agreement has an initial three-year term, which may be renewed by Biovest for additional one-year periods.
The supply agreement provides for Stellar and Biovest to consummate a separate quality agreement, within three months, to list the quality aspects and procedures relating to manufacture and release of the cGMP-compliant Stellar KLH?. Biovest will appoint Stellar as exclusive supplier of KLH in connection with the potential future commercialization of BiovaxIDtrademark, subject to negotiation and execution of commercial production and supply terms.
"Stellar's key growth initiative is to leverage our Stellar KLH? technology into multiple clinical pathways and the BiovaxIDtrademark program is a good example of the value of our core business for this purpose," said Frank Oakes, President and CEO of Stellar Biotechnologies, Inc. "There are many new KLH-based immunotherapies advancing in clinical trials and we are positioning Stellar to be the leading company capable of delivering the scalable, sustainable supplies of KLH that will be needed by these pharmaceutical pipelines."
"We are pleased to collaborate with Stellar Biotechnologies to continue the clinical progress of our active immunotherapy (BiovaxID) and are proud to work with Stellar in anticipation of our future commercial success," said Carlos Santos, Chief Executive Officer of Biovest. "BiovaxID immunotherapy has demonstrated ability in long-running clinical trials to elicit potent anti-tumor immune responses and extend remission duration in patients suffering from follicular non-Hodgkin's lymphoma. If approved, we anticipate that this product will offer an innovative adjuvant/consolidation vaccine strategy for patients with this disease."
About Biovest International, Inc.
Biovest International, Inc. is a pharmaceutical company focused in the field of active personalized immunotherapy development targeting life-threatening cancers of the blood system, marketing state-of-the-art bioreactors, and providing a full range of custom biomanufacturing services. Biovest's lead personalized cancer vaccine candidate BiovaxIDtrademark is an autologous active immunotherapy (personalized cancer vaccine) that targets follicular non-Hodgkin's lymphoma, mantle cell lymphoma, and potentially other B-cell malignancies. BiovaxIDtrademark has undergone three clinical trials conducted in collaboration with the U.S. National Cancer Institute (NCI) that have demonstrated BiovaxIDtrademark's ability to increase the duration of cancer remission following chemotherapy and to induce immune responses which correlate highly with long-term survival. Biovest is currently in the process of pursuing European marketing approval for BiovaxIDtrademark.
Nick Hodge pumped Stellar from .80 to 2.30 about a year or so ago. I'm not happy with these newsletters doing this but have taken advantage of the spike in pps. I have no shame....what can I say.
The monopoly of having the only sustainable and traceable supply of KLH. If a drug is approved then only a traceable supply can be used and only Stellar has that in being the only aquaculture facility anywhere. Stellar also has patents regarding the blood extraction procedure which doesn't harm the host. One final note is the facility got a nice surprise last year when they discovered that the limpets are reproducing in the tanks. I've been in and out of Stellar since 2010 and look forward to the day when approved drugs become reality. One or two approvals would strain inventory.Three or four might not be able to be fulfilled and that would cry quite the monopoly for Stellar and opportunities for its shareholders. Remember one thing, limpets harvested in the wild can only be used for research and only a traceable and documented supply can be used in drug production.
thank you KCAC for response;
if i understand well, it is not a monopoly on commercialization, but rather on "functional benignity" of KLH isolation vis-a-vis the living animal...
it should be said clearly, as financial letters do not present it like that...
I am a little late in replying, but I think that IF KLH is used in any vaccine and needed in quantity it is pretty obvious that restrictions will be put out by the US or CA governments to protect the mollusk. The science article I just posted referred to this.
The SA article says the other biotech company can extract KLH without killing the animal. I doubt this is true or if whoever harvests the KLH even cares whether they kill the mollusk or not. If something is put on the endangered species list, it is totally hands off. You cannot touch it or affect it in any way whatsoever. A prime example is the Manatee, some tourist in FL posted video of herself petting and even attempting to ride a very tame wild manatee. It was obvious that she had no ill intent and did not harm the animal but the video became very public and she was arrested facing some serious charges. I did not hear the outcome and hopefully she did not do jail time, but you can bet if she was trying to extract the blood of the manatee, she would be in Federal prison.
Another Newsletter touting this company as a teaser to buy their newsletter. I received this in an e mail today. It is a very informative article and quite the pump, I assume their subscribers already may have been given the article recently and may have been partly responsible for the nice uptick yesterday. This will probably not post in a workable format, so here is the link....
http://www.angelnexus.com/o/web/65254
header (images are being blocked)
Forward to a Friend
Having trouble viewing this issue? Click here.
Dear Reader,
Have you seen the rare footage I was able to capture?
If you remember where you were and how you felt after events like the moon landing and the killing of Osama bin Laden...
This video will leave you with similar effects.
It's fascinating stuff that has the medical world in a frenzy.
More importantly for you... it's creating serious wealth for early investors.
In fact, a small group of savvy folks already turned every dollar they invested into four.
And the best part? This is only the beginning. You can still get in on the ground floor.
In the coming weeks and months, we're going to see a whole new wave of millionaires created.
What you're about to see documents a miracle of scientific discovery unlike anything that's come before. And it all starts with what you see in the image below:
Miracle Scientific Discovery
I urge you to watch this video now to get a piece of the action.
You may not believe it, but I assure you it's real — and it's happening right now.
Once you realize the implications of the evidence in this video — including live footage of earth-shattering science — you'll be awestruck. You'll want to share it with everyone you know.
And here's the kicker: This discovery also presents one of the most lucrative investment opportunities I've ever seen.
Are you prepared to be amazed?
If so, I encourage you to watch this free video in full so you understand the entirety of what's going on here.
Call it like you see it,
Nick Hodge Signature
Nick Hodge
Editor and Creator, Early Advantage
This email was sent to wbuffett@gmail.com . You can manage your subscription and get our privacy policy here.
Outsider Club, Copyright © 2014, Angel Publishing LLC, 111 Market Place #720, Baltimore, MD 21202. No statement or expression of opinion, or any other matter herein, directly or indirectly, is an offer or the solicitation of an offer to buy or sell the securities or financial instruments mentioned. While we believe the sources of information to be reliable, we in no way represent or guarantee the accuracy of the statements made herein. Outsider Club does not provide individual investment counseling, act as an investment advisor, or individually advocate the purchase or sale of any security or investment. Neither the publisher nor the editors are registered investment advisors. Subscribers should not view this publication as offering personalized legal or investment counseling. Investments recommended in this publication should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company in question. Unauthorized reproduction of this newsletter or its contents by Xerography, facsimile, or any other means is illegal and punishable by law.
Please note: It is not our intention to send email to anyone who doesn't want it. If you're not sure why you're getting this e-letter, or no longer wish to receive it, get more info here, including our privacy policy and information on how to manage your subscription.
You should see this write up and video. I need to read this board more often. This is dated 10/16 by a Science reporter and very informative....
http://science.kqed.org/quest/video/in-rare-sea-snail-scientists-find-compound-that-could-help-cancer-patients/
Followers
|
20
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
290
|
Created
|
09/10/10
|
Type
|
Free
|
Moderators |
Bio-tech with a new cancer protein system.
Stellar Biotechnologies Files Key Patent for Company
9/9/2010 8:04:21 AM - Market Wire
PT. HUENEME, CA, Sep 09, 2010 (MARKETWIRE via COMTEX News Network) --
Stellar Biotechnologies, Inc. (PINKSHEETS: SBOTF) (TSX-V: KLH) announces filing for patent protection of inventions related to its native Immunogenic (IMG) KLH technology platform and immune status monitoring product portfolio. KLH (keyhole limpet hemocyanin) is presently the most pharmaceutically important ICP (immune carrier protein) and IMG KLH is the most effective immune stimulant for use in cancer, viral and parasite vaccines; animal vaccines; and diagnostic products. Patent claims include pharmaceutical grade compositions of matter, processes for manufacture and methods of use in a wide range of therapies.
John Sundsmo, Ph.D., VP Research and Intellectual Property, said, "With filing of this patent application Stellar has achieved an important milestone on the road to becoming the preeminent world leader in development and manufacture of pharmaceutical grade immune carrier proteins. We are very pleased with the progress achieved by our scientists and what this patent application tangibly demonstrates."
Corporate Website: www.StellarBiotechnologies.com Stellar News at Marketwire: http://www.marketwire.com/mw/search.do?params=&grpSearch=C&companyid=70788
About Stellar Biotechnologies, Inc. (PINKSHEETS: SBOTF) (TSX-V: KLH) - (www.StellarBiotechnologies.com): is a world leader in sustainable manufacturing of pharmaceutical grade immune carrier proteins (ICP), particularly with regard to the present most important pharmaceutical protein in this class, KLH (Keyhole Limpet Hemocyanin). This ancient evolutionary protein has a highly complex structure that makes it ideal for use in human and animal vaccines and diagnostic products. With partners and customers, its flagship Stellar KLH products are in the clinic, and on the way to being established as the only sustainable, long-term pharmaceutical source.
This news release does not constitute an offer to sell, or a solicitation of an offer to buy any of the Company's securities set out herein in the United States, or to, or for the benefit or account of, a U.S. Person or person in the United States. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Contact: Darrell Brookstein Executive VP, Business Development & Finance dbrookstein@stellarbiotech.com
SOURCE: Stellar Biotechnologies, Inc.
mailto:dbrookstein@stellarbiotech.com
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |